<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML><HEAD>
<META http-equiv=Content-Type content="text/html; charset=iso-8859-1">
<META content="MSHTML 6.00.2800.1400" name=GENERATOR>
<STYLE></STYLE>
</HEAD>
<BODY bgColor=#ffffff background="">
<DIV><FONT face=Verdana size=2>Gracias a Rafa Bravo y la Biblioteca del capitán
Morgan, me entero de un metanalisis acerca de la diferencia de efectividad y/o
potencia de los inhibidores de la bomba de protones, cuyo sumario adjunto.
Traducido al castellano: todos los IBP son iguales (y sin llegar a hablar de
genéricos)</FONT></DIV>
<DIV><FONT face=Verdana size=2>Cordiales salu2:</FONT></DIV>
<DIV><FONT face=Verdana size=2>Jose Ramon Garcia Solans<BR>Farmaceutico
comunitario. Zaragoza<BR>976 554 986</FONT></DIV>
<DIV><BR><FONT face=Verdana size=2>Systematic review: direct comparative trials
of the efficacy of proton pump inhibitors in the management of
gastro-oesophageal reflux disease and peptic ulcer disease N. VAKIL* & M. B.
FENNERTY Departments of Medicine, Sections of Gastroenterology, *University of
Wisconsin, Milwaukee, WI, USA and Oregon Health and Science University,
Portland, OR, USA<BR>Accepted for publication 31 July
2003<BR>SUMMARY<BR>Background: Five proton pump inhibitors are now available for
use in North America. Claims of differences in the clinical efficacy of
different strengths and/or agents have been made.<BR>Aim: To identify any
consistent evidence of differences in outcomes between agents or doses within
this class of drugs.<BR>Methods: A search of the medical literature was
performed in two electronic databases, and randomized controlled trials of
higher quality were included in the assessment.<BR>Results and conclusions:
Thirty-two trials met our criteria. No convincing data were found to indicate
that low doses of proton pump inhibitors are as effective as standard doses of
proton pump inhibitors in the healing of erosive oesophagitis or in the relief
of symptoms of gastro-oesophageal reflux disease; however, they may be as
effective as maintenance therapy for gastro-oesophageal reflux disease and
peptic ulcer disease. Differences were found between the standard doses of
proton pump inhibitors with regard to the onset of symptom relief in
gastro-oesophageal reflux disease (lansoprazole was faster than omeprazole,
and esomeprazole was faster than both lansoprazole and omeprazole) and the
healing of oesophagitis (esomeprazole was superior to both omeprazole and
lansoprazole). <BR>Despite these differences, there are as yet insufficient data
to establish the superiority of any one agent over all others across all
disease states treated with these agents.<BR><BR></FONT></DIV></BODY></HTML>